DOWNLOADS

We genome-widely identified inter-individually variable CpGs based on whole-genome bisulfite sequencing of ~100 Japanese. In this page, we provide summary data for ~24 million CpGs.

The summary data include the following columns.
  • chr: chromosome
  • pos: chromosomal position
  • Beta_mean.mono: Mean of DNA methylation level of monocytes
  • Beta_SD.mono: Standard deviation of DNA methylation level of monocytes
  • Beta_RI.mono: Reference interval of DNA methylation level of monocytes, which is good indicator of variability
  • Beta_mean.cd4t: Mean of DNA methylation level of CD4+ T cells
  • Beta_SD.cd4t: Standard deviation of DNA methylation level of CD4+ T cells
  • Beta_RI.cd4t: Reference interval of DNA methylation level of CD4+ T cells
  • Beta_mean.neu: Mean of DNA methylation level of neutrophils
  • Beta_SD.neu: Standard deviation of DNA methylation level of neutrophils
  • Beta_RI.neu: Reference interval of DNA methylation level of neutrophils


TERMS & CONDITIONS

The summary data will only be provided to persons who have agreed to the following Rules of Use. In other words, a person who has downloaded the data shall be deemed to have read and understood the contents stated in the provisions of the Rules of Use and to have agreed the stated obligations [(i) prohibition on identifying and contacting any person who has provided specimens which were used for constituting the summary data; (ii) use of the summary data for non-commercial purposes only; (iii) notification at the time of re-editing the summary data; (iv) citation of IMM theses at the time of publishing the results, etc.]. You are requested to download the summary only after having understood the foregoing. The copyrights in and to the summary data and the database are owned by IMM.

*The change in our policy for opening data of genomic analysis of cohort participants was made after sincere consideration by the members of Ethical, Legal, and Social Issues (ELSI) Committee and Sample and Data Access Committee for the Tohoku Medical Megabank Project regarding the following points.


  1. Protection of privacy of the participants and possibility of identification/specification of the participants.
    • It is almost impossible to identify participants of the cohort study through only average and variation of DNA methylation level of CpGs because no individual data is disclosed at the iMEHTYL site. Furthermore, users of the genomic data should agree to the following terms: prohibition of identification/specification of the participants by combining the data and other possibly available social, biological, and clinical data.
    • To exclude the possibility that a participant is identified by the summary data of DNA methylation in combination with epidemiological data (social, biological, or clinical information), epidemiological data would be released in a way that disallows easy connection of the genomic and epidemiological data.

  2. Variations associated with the diseases
    • The DNA methylation information released at this time may prove to be strongly associated with a certain disease. At the same time, we recognize that such data in our panel inevitably include a certain amount of error as a natural consequence of using next-generation sequencers and statistical methods to measure the DNA methylation level. We think that our current data set has not yet met the quality required to estimate and report an individual's risk for the disease as is present in clinical settings. We have to accurately inform users of the data set to the current limitation of the genomic analysis data.
    • The Medical Megabank Project seeks the possible return of reliable and beneficial genetic analysis results to the cohort participants. However, we must establish validation processes before we begin to inform participants of the genotype results, because as stated above, our current data were derived from a pipeline of next-generation sequencer analysis, and such data are not accurate enough for the individual return of the DNA methylation data.

*Any personal information registered by you with IMM for the use of the database shall be used solely for the purpose of managing the User's use of the database and shall not be provided or disclosed to any third parties.

*If you have any inquiries on the information stored in the database or if you find any person who is improperly using such information, please contact us at the following e-mail address: megabankATjDOTiwate-medDOTacDOTjp (Please replace “AT” with “@” and “DOT” with “.”).

*We plan to improve the database in the future by adding further information, provided, however, that, in such case, you may be requested to use such information under stricter conditions in terms of ensuring the protection of personal information.


Agree terms and conditions:
Name:
Institute:
Email address:
pagetop